05 September 2012

Spain’s Almirall opens a new subsidiary in Toronto, Canada

Barcelona – 05 ​​September 2012. - Almirall SA has announced the opening of a new subsidiary in Canada with that established for the first time, direct presence in U.S. territory. The branch will be located in Toronto, an area that is distinguished by its high level biopharmaceutical industry. 

"Almirall will now be made available to Canadian patients, directly, a range of innovative medicines, particularly in the areas of respiratory and dermatology," says Eduardo Sanchiz, CEO of Almirall. "This is another milestone in our internationalization process, a major challenge we face with enthusiasm," he adds. 

In the Canadian pharmaceutical business (the 8th global one), respiratory and dermatology segments of the market are important and both are key therapeutic areas where R & D focuses Almirall. 

Aclidinium-Almirall drug recently approved for COPD in the United States and Europe will be one of the first drugs available in the new subsidiary, where the respiratory franchise will be co-promoted aclidinium with Forest. Financial details of the agreement were not disclosed. 

With the opening of its branch number 13, Almirall takes another step in its internationalization process. 

aclidinium bromide inhalation powder is an anticholinergic indicated for the treatment of long-term maintenance of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Almirall has licensed rights for aclidinium U.S. Forest Laboratories, Inc., Kyorin Pharmaceutical Co. Ltd in Japan and Daewoong Pharmaceutical Co. Ltd in Korea. Almirall also has given co-marketing rights in most EU member states and a number of non-EU countries to Menarini. Almirall maintains rights for the rest of the world. 

Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona (Spain). Almirall researches, develops, manufactures and markets pharmaceuticals R & D and licensing, with the goal of improving the health and wellbeing of people. The therapeutic areas on which Almirall focuses its research resources are respiratory, gastrointestinal, dermatological and pain. Almirall's products are present in more than 70 countries on five continents. It has direct presence in Europe, Mexico and Canada through 13 subsidiaries. 

Source: Almirall